Abstract
We treated 23 patients with sudden hearling loss by intravenous administration of amidotrizoate (60% Urografin) after conventional therapy. The patients were initially treated with prednisolone, Vitamine B12, stellate ganglion block, and hyperbaric oxygen. Conventional therapy led to a partial recovery of hearing acuity and vertigo in 26.1% of the patients. However, there was no change in symptoms in the other patients. Twenty milliliters of amidotrizoate was intravenously administered every day for a week. Following treatment with amidotrizoate, a complete, marked, and partial recovery of symptoms was observed in 4.3%, 17.4%, and 34.8% of the patients, respectively. However, 43.5% of the patients showed no change in symptoms. No side effects were observed following amidotrizoate therapy. We conclude that intravenous administration of amidotrizoate may recover hearing in patients with sudden deafness.
